Newly published Network Meta-Analysis (NMA) from Janssen indirectly compares all published Phase III data for approved treatments for adults with active Psoriatic Arthritis (PsA).
List view / Grid view
At week 48 of the Phase II trial, 65 percent of patients with Crohn's disease receiving Tremfya® achieved clinical remission.
Tremfya inhibited radiographic progression and provided durable improvements in symptoms of axial involvement in psoriatic arthritis patients.
Over 50 percent of psoriatic arthritis patients treated with Tremfya® (guselkumab) achieved ≥20 percent improvement in joint symptoms and complete skin clearance at one year.
The joint and skin response rates of adults with active psoriatic arthritis observed with Tremfya® (guselkumab) were maintained over two years.
Ten medicines have been recommended for marketing authorisation and 10 extensions of indication have been suggested by the EMA.